Monoclonal antibody fragments (Fab) are a promising class of therapeutic agents. Fabs are
aglycosylated proteins and so many expression platforms have been developed including …

Monoclonal antibodies are increasingly being used as therapeutic agents in a wide range of
indications, including oncology, inflammation and infectious disease. In most cases the …

Many early drug candidates derived from biotechnology failed in clinical trials because of
their low affinity/specificity, short half-lives or immunogenicity. Protein engineering …

The exquisite binding specificity of antibodies has made them valuable tools from the
laboratory to the clinic. Since the description of the murine hybridoma technology by Köhler …

The intracellular expression of highly specific antibody fragments (“intrabodies”) in
eukaryotes has a great potential in functional genomics and therapeutics. However, since …

Various forms of recombinant monoclonal antibodies are being used increasingly, mainly for
therapeutic purposes. This review specifically focuses on what is now called antibody …

Antibody engineering has become a well-developed discipline, encompassing discovery
methods, production strategies, and modification techniques that have brought forth …

Recombinant antibodies and their fragments now represent over 30% of all biological
proteins undergoing clinical trials, which recently culminated in FDA approval for the first …

Antibodies (Abs) are some of the most powerful tools in therapy and diagnostics and are
currently one of the fastest growing classes of therapeutic molecules. Recombinant antibody …

Fabs are an important class of antibody fragment as both research reagents and therapeutic
agents. There are a plethora of methods described for their recombinant expression and …